

VERTEX PHARMA - Unlikely to Tap the Cystic Fibrosis market Beyond G551D Mutation!

<https://marketpublishers.com/r/VD845AFAFACEN.html>

Date: June 2011

Pages: 4

Price: US\$ 90.00 (Single User License)

ID: VD845AFAFACEN

Abstracts

Vertex (VRTX) strategy to tap the larger Cystic Fibrosis market of Δ F508 mutation by combination of a potentiator (VX-770) and corrector (VX-809) of the underlying genetic defect in CF pts did not yield data (reduction in sweat chloride of -9.10 mmol/L (p

Contents

COMPANIES MENTIONED

VERTEX, VRTX

I would like to order

Product name: VERTEX PHARMA - Unlikely to Tap the Cystic Fibrosis market Beyond G551D Mutation!

Product link: <https://marketpublishers.com/r/VD845AFAFACEN.html>

Price: US\$ 90.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/VD845AFAFACEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970